🇺🇸 FDA
Pipeline program

Esketamine

IRB-20230021-R

Approved small_molecule active

Quick answer

Esketamine for Postpartum Depression is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Postpartum Depression
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials